GeoVax to Raise Approximately $8.5 Million
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company in the clinical stage that specializes in developing immunotherapies and vaccines for cancer and infectious diseases, has signed a definitive securities purchase agreement with an institutional investor. This agreement involves the purchase and sale of 1,700,000 shares of the Company’s common stock, priced at $5.00 per share, in a registered direct offering that is priced above the market according to Nasdaq regulations.
Warrants and Concurrent Private Placement
Additionally, as part of a concurrent private placement, the Company will issue warrants allowing the purchase of up to 1,700,000 shares of common stock. These warrants will have an exercise price of $5.00 per share, can be exercised immediately upon issuance, and will remain valid for five years.
Proceeds and Use of Funds
The Company anticipates gross proceeds from this offering to be around $8.5 million, before accounting for placement agent fees and other expenses related to the offering. The net proceeds are intended for working capital and various corporate purposes.
Shelf Registration Statement
The shares being offered are part of a shelf registration statement on Form S-3 that has been filed with the Securities and Exchange Commission (SEC) and has received effective status. The offering will be conducted solely through a prospectus, which includes a prospectus supplement that is part of the effective registration statement.
About GeoVax
GeoVax Labs, Inc. is dedicated to creating innovative vaccines for infectious diseases and therapies for solid tumor cancers. The company’s primary clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine that is currently undergoing multiple Phase 2 clinical trials. Furthermore, it is also working on a groundbreaking gene-directed therapy aimed at treating advanced head and neck cancers.
Leadership and Expertise
GeoVax boasts a robust intellectual property portfolio and a leadership team with extensive experience in generating significant value within life science companies. For more details on the current status of clinical trials and other updates, please visit the company’s website.
Frequently Asked Questions
What is the purpose of GeoVax's recent offering?
The offering is designed to raise funds for working capital and general corporate purposes.
How much gross proceeds is GeoVax expecting to raise?
GeoVax anticipates raising approximately $8.5 million in gross proceeds from the offering.
Who is the placement agent for this offering?
Roth Capital Partners is serving as the exclusive placement agent for this offering.
What is GEO-CM04S1?
GEO-CM04S1 is GeoVax's next-generation COVID-19 vaccine that is currently being evaluated in Phase 2 clinical trials.
What types of diseases is GeoVax focused on?
GeoVax is concentrating on the development of immunotherapies and vaccines aimed at combating cancer and infectious diseases.
